Paul Peloso, MD profile page

Paul M. Peloso, MD, joined COUR in 2024 as Chief Medical Officer where he leads the company’s clinical development programs. Dr. Peloso has 20 years of experience in industry, with tenures at larger pharma including Amgen, Merck/MSD and Abbvie. He has spent the later part of his career at smaller biotech. Prior to joining COUR, Dr. Peloso served as Chief Medical Officer for ACELYRIN, Inc., a biopharma company focused on providing life-changing new treatment options for patients by employing a strategy of identifying, acquiring and accelerating development and commercialization of promising drug candidates. While at ACELYRIN, Dr. Peloso was responsible for global clinical development of the company’s pipeline of products, with an initial focus in immunology. Dr. Peloso was previously vice president and therapeutic head for rheumatology of Horizon Therapeutics, where he was responsible for advancing the company’s pipeline of first-in-class rare disease medicines including, notably KRYSTEXXA® until its acquisition by Amgen in 2023. Prior to this role, Dr. Peloso served as group medical director for both AbbVie and Merck, where he leveraged his extensive experience in biologics, small molecules, and medical devices. Among Dr. Peloso’s global clinical and regulatory achievements across his career, he helped develop and ultimately secure approvals for KRYSTEXXA® ORILISSA® (elagolix), ILUMYA™ (tildrakizumab), Arcoxia® (etoricoxib), and Enbrel® (etanercept). Prior to entering the industry, Dr. Peloso was in academic practice in rheumatology in the U.S. and Canada. He holds two bachelor’s degrees, one in biochemistry and another in sociology, from McMaster University and earned his medical degree from the University of Calgary before training in rheumatology and epidemiology.